A Study to Investigate the Efficacy and Tolerability of ESO-101 in Patients With Eosinophilic Esophagitis

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

June 29, 2021

Primary Completion Date

October 9, 2023

Study Completion Date

October 9, 2023

Conditions
Eosinophilic Esophagitis
Interventions
DRUG

ESO-101

Daily administration in the evening at bedtime for 28 days

DRUG

Placebo

Daily administration in the evening at bedtime for 28 days

Trial Locations (17)

Unknown

Facharztzentrum Eppendorf, Hamburg

Universitätsklinikum Leipzig AöR, Leipzig

Otto-von-Guericke-Universität Medizinische Fakultät Universitätsklinikum Magdeburg A. ö. R., Magdeburg

Klinikum rechts der Isar der TUM, München

Amsterdam University Medical Center, Amsterdam

Albert Schweitzer Ziekenhuis, Dordrecht

Centrum Medyczne Med-GASTR Sp. z o.o., Lodz

Centrum Medyczne Sonomed Sp. z o.o., Szczecin

Hospital Universitario Vall d' Hebrón, Barcelona

Hospital Universitario de La Princesa, Madrid

Hospital Universitario Fundación Jiménez Díaz, Madrid

Hospital Universitario Central De Asturias, Oviedo

Hospital de Navarra, Pamplona

Hospital General de Tomelloso, Tomelloso

Hospital Universitario Rio Hortega, Valladolid

Hospital de Viladecans, Viladecans

Universitätsspital Zürich, Zurich

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

FGK Clinical Research GmbH

INDUSTRY

collaborator

FGK Representative Service B.V.

UNKNOWN

lead

EsoCap AG

INDUSTRY